<DOC>
	<DOCNO>NCT02231177</DOCNO>
	<brief_summary>The purpose study compare systemic exposure BI 1744 BS tiotropium steady state follow inhalation fix dose combination ( FDC ) 10 μg BI 1744 CL plus 5 μg tiotropium bromide systemic exposure BI 1744 BS tiotropium steady state follow inhalation single agent , i.e. , 10 μg BI 1744 CL 5 μg tiotropium bromide , administer once-daily via Respimat® Inhaler 21 day . The secondary objective compare safety tolerability ( adverse event , 12-lead electrocardiogram recording , pulmonary function test ) BI 1744 CL tiotropium bromide administer fix dose combination single-agent therapy .</brief_summary>
	<brief_title>Pharmacokinetics Safety BI 1744 CL Plus Tiotropium Bromide Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>1 . All patient must sign informed consent consistent International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline local legislation prior studyrelated procedure , include medication washout restriction 2 . All patient must diagnosis COPD must meet follow spirometric criterion : Patients must relatively stable airway obstruction postbronchodilator force expiratory volume one second ( FEV1 ) ≥ 30 % predict normal &lt; 80 % predict normal postbronchodilator FEV1 / force vital capacity ( FVC ) &lt; 70 % Visit 1 3 . Male female patient , 40 year age old 4 . Patients must current exsmokers smoke history 10 pack year 5 . Patients must able perform technically acceptable pulmonary function test study period require protocol 6 . Patients must able inhale medication competent manner Respimat® inhaler meter dose inhalator ( MDI ) 1 . Patients significant disease COPD ; significant disease define disease , opinion investigator , may ( ) put patient risk participation study , ( ii ) influence result study , ( iii ) cause concern regard patient 's ability participate study 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry urinalysis ; patient serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 2.5 x ULN , serum glutamic pyruvic transaminase ( SGPT ) &gt; 2.5 x ULN , bilirubin &gt; 2x upper limit normal ( ULN ) , creatinine &gt; 2 x ULN creatinine clearance &lt; 50 mL/min ( Estimation Glomerular Filtration Rate ( GFR ) use CockcroftGault Formula ) exclude regardless clinical condition ( repeat laboratory evaluation conduct patient ) 3 . Patients history asthma total blood eosinophil count ≥600/mm3 4 . Patients follow condition : diagnosis thyrotoxicosis diagnosis paroxysmal tachycardia ( &gt; 100 beat per minute ) mark baseline prolongation QT/QTc interval history additional risk factor Torsade de Pointes ( TdP ) ( e.g . heart failure , hypokalaemia , family history Long QT Syndrome ) 5 . Patients follow condition : history myocardial infarction within 1 year screen visit ( Visit 1 ) diagnosis cardiac arrhythmia , arterial hypertension coronary heart disease know active tuberculosis malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient treat basal cell carcinoma allow ) history lifethreatening pulmonary obstruction history cystic fibrosis clinically evident bronchiectasis history significant alcohol drug abuse 6 . Patients undergone thoracotomy pulmonary resection 7 . Patients treat follow concomitant medication : medication prolong QT/QTc interval since effect BI 1744 CL QT/QTc interval yet fully characterize oral βadrenergics βblockers ( topical β blocker ocular condition allow ) oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day 8 . Patients regularly use daytime oxygen therapy one hour per day investigator 's opinion unable abstain use oxygen therapy clinic visit 9 . Patients complete pulmonary rehabilitation program six week prior Screening Visit ( Visit 1 ) patient currently pulmonary rehabilitation program 10 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit ( Visit 1 ) 11 . Patients know hypersensitivity βadrenergics and/or anticholinergic drug , benzalkonium chloride , ethylenediaminetetraacetic acid component Respimat® inhalation solution delivery system 12 . Pregnant nursing woman 13 . Women childbearing potential use two highly effective method birth control ( one barrier one nonbarrier ) . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomise partner . Female patient consider childbearing potential unless surgically sterilise hysterectomy bilateral tubal ligation , postmenopausal least two year 14 . Patients previously randomize study currently participate another study 15 . Patients unable comply pulmonary medication restriction prior randomization 16 . According Inclusion Criterion No . 2 , patient postbronchodilator FEV1 &lt; 30 % predict normal always exclude . Patients postbronchodilator FEV1 30 50 % predict normal excluded study , display additional symptom chronic respiratory insufficiency right ventricular insufficiency 17 . Patients narrow angle glaucoma , prostate hyperplasia , bladder neck obstruction</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>